26 results about "Prurigo nodularis" patented technology

The invention discloses an application of betulinic acid 28-O-beta-D-glucoside (BA-6 for short) in preparation of a medicine for preventing and treating skin inflammation. The problems that an existing medicine for treating dermatitis is limited in curative effect, slow in effect taking, multiple in side effect, high in long-term use risk, large in individual difference, high in treatment cost, likely to cause immunoreaction and the like are solved. The invention discloses application of BA-6 in prevention and treatment of atopic dermatitis, contact dermatitis, eczema, rash, psoriasis, lupus erythematosus, papule squamous skin disease, pityriasis rosea, seborrheic dermatitis, pemphigus, celestial abscess, acne, tinea corporis, impetigo, SAPHO syndrome, hidradenitis suppurativa, dermatitis caused by drugs, lichen planus, pityriasis rubra pilaris, vitiligo, prurigo nodularis, dermatitis caused by drugs, and the like for the first time. The traditional Chinese medicine composition can be used for treating skin diseases, systemic sclerosis, hidradenitis suppurativa, granulomatous skin diseases, vitiligo, dermatomyositis, chronic skin itch and alopecia areata, and has the technical progress of obviously improving skin erythema, papule, edema, scale, moss and ulceration symptoms.

Methods for treating itch in human patients with atopic dermatitis (AD) and / or prurigo nodularis (PN) comprising administering a therapeutically effective amount of at least one compound chosen from (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3- yl)piperazin-1-yl]pent-2-enenitrile (rilzabrutinib) and pharmaceutically acceptable salts thereof are disclosed.

The disclosure relates to compounds of the disclosure and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of disease(s) such as atopic dermatitis, eosinophilic gastritis, atopic keratoconjunctivitis, allergy, alopecia, Alzheimer's disease, asthma, atherosclerosis, Bechet's disease, bullous pemphigoid, cancer, chronic obstructive pulmonary disease, chronic pruritis, chronic urticaria, Crohn's disease (CD), dermatitis, diabetic kidney disease, eosinophilic esophagitis, fungal keratitis, gout, idiopathic pulmonary fibrosis (IPF), keloids, non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis, prurigo nodularis, psoriasis, psoriatic arthritis, rhinosinusitis, scleroderma, systemic lupus erythematosus (SLE), systemic sclerosis, ulcerative colitis (UC), vitiligo, or hidradenitis suppurativa. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of a dermatological condition or a respiratory condition.

Described herein are the treatment and prophylaxis of prurigo nodularis (PN), antibodies and pharmaceutical compositions for the treatment or prophylaxis of PN, and the use of an anti-IL-31RA antibody, such as nemolizumab, in the manufacture of a medicament for the treatment or prophylaxis of PN. Also described herein are biomarkers of PN and methods of altering or ameliorating these biomarkers by treatment with an antibody that binds to IL-31 RA (e.g., nemolizumab).

The present invention relates to an antisense oligonucleotide targeting an interleukin 4 receptor and the use thereof. The antisense oligonucleotide (ASO) molecule has a length of 16-22 bases and is specifically paired with a specific region of a target gene (interleukin 4 receptor). The ASO is used for treating diseases associated with IL-4Rα, which includes, but is not limited to, asthma (including eosinophilic asthma), atopic dermatitis, eosinophilic esophagitis, sinusitis, nasal polyps, prurigo nodularis, urticaria, chronic obstructive pulmonary disease, bullous pemphigoid, pruritus, and gastritis.

Provided herein are polypeptides that bind IL31 and methods of using IL31-binding polypeptides to modulate the biological activity of IL31. Also provided herein are nucleic acids, host cells, and methods of preparing polypeptides that bind IL31. Uses and methods provided herein include, but are not limited to, methods of treating an IL31-associated condition, such as a pruritic condition, atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria. Also provided herein are methods of detecting using the polypeptides that bind IL31.

Described herein are treatments and preventions for prurigo nodularis (PN), antibodies and pharmaceutical compositions for use in the treatment or prevention of PN, and the use of anti-IL-31RA antibodies (e.g., nemolizumab) in the manufacture of a medicament for the treatment or prevention of PN. Also described herein are biomarkers for PN and methods of altering or ameliorating these biomarkers through treatment with an antibody that binds to IL-31RA (e.g., nemolizumab).

The invention provides a method for treating prurigo nodularis by administering an anti-OX40 or anti- OX40L inhibitor, and an article of manufacture with instructions for such use. In particular the invention relates to a dosage regiment wherein an anti-OX40 antibody is administered at a dose of between about 150 mg and 300 mg once every 4 weeks, with an additional loading dose of anti-OX40 antibody between about 150 mg and 300 mg at week 2.

This disclosure relates to ruxolitinib, or a pharmaceutically acceptable salt thereof, and its use in treating prurigo nodularis.

Provided herein are co-binders that bind IL13 and methods of using IL13 co-binders to modulate the biological activity of IL13. Also provided herein are nucleic acids, host cells, and methods of preparing co-binders that bind IL13. Uses and methods provided herein include, but are not limited to, methods of treating an IL13-associated condition, such as a pruritic condition, atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria. Also provided herein are methods of detecting using the co-binders that bind IL13.

The invention belongs to the technical field of biological medicine, and particularly relates to a biomarker of prurigo nodularis and application of the biomarker. The invention discloses that protease activated receptor 2 (PAR2) regulates expression of Th2 type cytokines through a G alpha12-RhoA-ERK signal channel for the first time, and further participates in morbidity of prurigo nodularis (PN). According to the embodiment of the invention, various experimental means such as qRT-PCR, Western Blot, IHC, IF and the like are utilized to verify expression up-regulation of PAR2 and related molecules in skin tissues of a PN patient and the correlation of the PAR2 and related molecules with clinical symptoms. Molecules such as PAR2, RhoA, ERK, IL-4, IL-31 and the like are proved to be highly related to pathological characteristics of PN. The molecules can be used as diagnostic markers or target spots for treating prurigo nodularis, and can be used for early diagnosis of PN, disease assessment or drug development.

The presently disclosed subject matter is directed to an effective method of treating chronic kidney disease-associated pruritus. Particularly, the method comprises the transmucosal administering of nalmefene to treat chronic kidney disease-associated pruritus, as well as cholestatic pruritus and / or prurigo nodularis. The nalmefene can be configured in a single layer film comprising at least two distinct domains. The film can include a first discrete domain comprising about 50-100 weight percent polymer matrix and the second discrete domain can comprise the nalmefene or pharmaceutically acceptable nalmefene salt.

Provided herein are bispecific polypeptides that bind IL13 and IL31 and methods of using IL13 and IL31 bispecific polypeptides to modulate the biological activity of IL13 and / or IL31. Also provided herein are nucleic acids, host cells, and methods of preparing polypeptides that bind IL13 and IL31. Uses and methods provided herein include, but are not limited to, methods of treating an IL13-associated condition and / or an IL31-associated condition, such as a pruritic condition, atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria.

This disclosure relates to JAK1 pathway inhibitors and their use in treating prurigo nodularis.

Provided herein are bispecific polypeptides that bind IL13 and IL31 and methods of using IL13 and IL31 bispecific polypeptides to modulate the biological activity of IL13 and / or IL31. Also provided herein are nucleic acids, host cells, and methods of preparing polypeptides that bind IL13 and IL31. Uses and methods provided herein include, but are not limited to, methods of treating an IL13-associated condition and / or an IL31-associated condition, such as a pruritic condition, atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria.

Provided herein are polypeptides that bind IL31 and methods of using IL31-binding polypeptides to modulate the biological activity of IL31. Also provided herein are nucleic acids, host cells, and methods of preparing polypeptides that bind IL31. Uses and methods provided herein include, but are not limited to, methods of treating an IL31-associated condition, such as a pruritic condition, atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria. Also provided herein are methods of detecting using the polypeptides that bind IL31.

Disclosed herein, in part, are pharmaceutical compositions comprising dupilumab and arginine-glutamate and methods of using the pharmaceutical compositions to treat medical disorders e.g., atopic dermatitis, eosinophilic esophagitis, prurigo nodularis, asthma, or chronic rhinosinusitis in a patient in need thereof.

Provided herein are bispecific polypeptides that bind IL13 and IL31 and methods of using IL13 and IL31 bispecific polypeptides to modulate the biological activity of IL13 and / or IL31. Also provided herein are nucleic acids, host cells, and methods of preparing polypeptides that bind IL13 and IL31. Uses and methods provided herein include, but are not limited to, methods of treating an IL13-associated condition and / or an IL31-associated condition, such as a pruritic condition, atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria.

The invention discloses an anti-IL-31 antibody and an application thereof. The antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 of which the amino acid sequences are respectively shown as SEQ ID NO: 32, SEQ ID NO: 33 and SEQ ID NO: 34; the light chain variable region comprises an LCDR1, an LCDR2 and an LCDR3, wherein the amino acid sequences of the LCDR1, the LCDR2 and the LCDR3 are respectively shown as SEQ ID NO: 35, SEQ ID NO: 36 and SEQ ID NO: 37. The antibody disclosed by the invention can be specifically combined with a cytokine IL-31, and block the combination of the IL-31 and a receptor IL-31RA, so that the activation of a downstream signal channel is further inhibited, and the inflammatory response can be effectively reduced. The pharmaceutical composition containing the anti-IL-31 antibody can be used for the treatment or prevention of atopic dermatitis, pruritus, prurigo nodularis and systemic sclerosis.

Provided herein are polypeptides that bind IL31 and methods of using IL31-binding polypeptides to modulate the biological activity of IL31. Also provided herein are nucleic acids, host cells, and methods of preparing polypeptides that bind IL31. Uses and methods provided herein include, but are not limited to, methods of treating an IL31-associated condition, such as a pruritic condition, atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria. Also provided herein are methods of detecting using the polypeptides that bind IL31.

Provided herein are co-binders that bind IL13 and methods of using IL13 co-binders to modulate the biological activity of IL13. Also provided herein are nucleic acids, host cells, and methods of preparing co-binders that bind IL13. Uses and methods provided herein include, but are not limited to, methods of treating an IL13-associated condition, such as a pruritic condition, atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria. Also provided herein are methods of detecting using the co-binders that bind IL13.

This disclosure relates to JAK1 pathway inhibitors and their use in treating prurigo nodularis.

The present disclosure relates to compounds represented by structural formula (I*): such as 1H-pyrrolo[2,3-b]pyridine derivatives, or a pharmaceutically acceptable salt thereof. Further disclosed are pharmaceutical compositions comprising the compounds, and the compounds for use in methods of treating MRGPRX2-mediated diseases or disorders, such as inflammatory diseases, e.g. chronic spontaneous urticaria, chronic inducible urticaria, mastocytosis, atopic dermatitis, rosacea, Crohn's disease, ulcerative colitis, irritable bowel syndrome, rheumatoid arthritis, fibromyalgia, nasal polyps, neuropathic pain, inflammatory pain, chronic itch, drug-induced anaphylactoid reactions, metabolic syndrome, oesophagus reflux, asthma, cough, migraine, chronic pruritus, acute pruritus, prurigo nodularis, osteoarthritis, and pseudo anaphylaxis.

Provided herein are polypeptides that bind IL31 and methods of using IL31-binding polypeptides to modulate the biological activity of IL31. Also provided herein are nucleic acids, host cells, and methods of preparing polypeptides that bind IL31. Uses and methods provided herein include, but are not limited to, methods of treating an IL31-associated condition, such as a pruritic condition, atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria. Also provided herein are methods of detecting using the polypeptides that bind IL31.

Provided herein are polypeptides that bind IL31 and methods of using IL31-binding polypeptides to modulate the biological activity of IL31. Also provided herein are nucleic acids, host cells, and methods of preparing polypeptides that bind IL31. Uses and methods provided herein include, but are not limited to, methods of treating an IL31-associated condition, such as a pruritic condition, atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria. Also provided herein are methods of detecting using the polypeptides that bind IL31.